ରାନିଟିଡିନ

ରାନିଟିଡିନ
Clinical data
Pronunciation	/rəˈnɪtɪdiːn/
Trade names	Zantac, others
Synonyms	Dimethyl [(5-{[(2-{[1-(methylamino)-; 2-nitroethenyl]amino}ethyl)sulfanyl]; methyl}furan-2-yl)methyl]amine
AHFS/Drugs.com	monograph
MedlinePlus	a601106
data	US FDA: Ranitidine;
Pregnancy; category	AU: B1 ; US: B (No risk in non-human studies) ; ;
Routes of; administration	Oral, IV
ATC code	A02BA02 (WHO) ; A02BA07 (ranitidine bismuth citrate);
Legal status
Legal status	AU: S2 (Pharmacy only) ; UK: General sales list (GSL, OTC) ; US: OTC / Rx-only;
Pharmacokinetic data
Bioavailability	39 to 88%
Protein binding	15%
Metabolism	Hepatic: FMOs, including FMO3; other enzymes
Onset of action	55–65 minutes (150 mg dose); 55–115 minutes (75 mg dose)
Elimination half-life	2–3 hours
Excretion	30–70% Renal
Identifiers
	IUPAC name N-(2-[(5-[(dimethylamino)methyl]furan-2-yl)methylthio]ethyl)-N'-methyl-2-nitroethene-1,1-diamine;
CAS Number	66357-35-5 ;
PubChem CID	3001055;
IUPHAR/BPS	1234;
DrugBank	DB00863 ;
ChemSpider	4863 ;
UNII	884KT10YB7;
KEGG	D00422 ;
ChEBI	CHEBI:8776 ;
ChEMBL	CHEMBL1790041 ;
ECHA InfoCard	100.060.283
Chemical and physical data
Formula	C13H22N4O3S
Molar mass	314.4 g/mol
3D model (JSmol)	Interactive image;
	SMILES CNC(=C[N+](=O)[O-])NCCSCc1ccc(o1)CN(C)C;
	InChI InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3 ; Key:VMXUWOKSQNHOCA-UHFFFAOYSA-N ;
(what is this?) (verify)

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Ranitidine

ରାନିଟିଡିନ, ଏକ ବିକ୍ରୟ ନାମ ଜାନଟାକ, ଏକ ପ୍ରକାର ଔଷଧ ଯାହା ଅମ୍ଳରୋଗ, ଗ୍ୟାସ୍ଟ୍ରୋଏସୋଫେଜିଆଲ ରିଫ୍ଲକ୍ସ ଡିଜିଜ ଓ ଜଲିଞ୍ଜର ଏଲିସନ ସିଣ୍ଡ୍ରୋମ ରୋଗ ଚିକିତ୍ସାରେ ବ୍ୟବ‌ହାର କରାଯାଏ । ^[୨] ହାଇଭ୍ସରେ ଉପକାର ମିଳିବା ଭଳି କୌଣସି ପ୍ରମାଣ ମିଳିନାହିଁ ।^[୩] ଏହାର ପାଟିରେ ବା ମାଂସପେଶୀ ଇଞ୍ଜେକସନ ଓ ଶିରାଭ୍ୟନ୍ତର ଇଞ୍ଜେକସନ ଆକାରରେ ଦିଆଯାଇପାରେ । ^[୨]

ରାନିଟିଡିନ ଇଞ୍ଜେକସନ ଦେଲେ ମୁଣ୍ଡବଥା, ଇଞ୍ଜେକସନ ନେଇଥିବା ଜାଗାରେ କଷ୍ଟ ଓ ଜଳାପୋଡ଼ା ଭଳି ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ହୁଏ । ସାଂଘାତିକ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ମଧ୍ୟରେ ଯକୃତ ସମସ୍ୟା, କମ ହୃତସ୍ପନ୍ଦନ ହାର, ନିମୋନିଆ ଓ ସମ୍ଭାବ୍ୟ ପାକସ୍ଥଳୀ କର୍କଟ ଲକ୍ଷଣ ଲୁଚିଯିବା ସଙ୍କଟ ହୋଇପାରେ ।^[୨] କ୍ଲସ୍ଟ୍ରିଡିଅମ ଡିଫିସିଲ କୋଲାଇଟିସ ରୋଗ ହେବା ସଙ୍କଟ ଅଧିକ ହୁଏ ।^[୪] ଗର୍ଭାବସ୍ଥାରେ ସାଧାରଣତଃ ଏହା ବିପଦମୁକ୍ତ ଥାଏ । ଏହାଦ୍ୱାରା ପାକସ୍ଥଳୀର ଜୀବକୋଷରୁ କ୍ଷରିତ ଅମ୍ଳ ପରିମାଣ କମିଯାଏ, ତେଣୁ ଏହାକୁ ହିସ୍ଟାମିନ ରିସେପ୍ଟର ଆଣ୍ଟାଗୋନିସ୍ଟ କୁହାଯାଏ ।^[୨]

ସନ ୧୯୭୬ରେ ଗ୍ଲାକ୍ସୋ ଫାର୍ମାସିଉଟିକାଲଦ୍ୱାରା (ଅଧୁନା ଗ୍ଲାକ୍ସୋସ୍ମିଥ କ୍ଲାଇନର ଏକା ଅଂଶ) ରାନିଟିଡିନ ଆବିଷ୍କୃତ ହୋଇଥିଲା । ^[୫]^[୬] ଏହାର ନାମ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଅତ୍ୟାବଶ୍ୟକୀୟ ଔଷଧ ଚିଠାରେ ଅଛି ଯାହା ମୌଳିକ ସ୍ୱାସ୍ଥ୍ୟ ସିସ୍ଟମ ନିମନ୍ତେ ଅତି ମହତ୍ତ୍ୱପୂର୍ଣ୍ଣ ।^[୭] ଏହା ଜେନେରିକ ଔଷଧ ନାମରେ ଉପଲବ୍‌ଧ ହୁଏ ।^[୨] ପିଲ ପିଛା ଏହାର ମୂଲ୍ୟ ୦.୦୧ରୁ ୦.୦୬ ଆମେରିକୀୟ ଡଲାର ।^[୮] ଯୁକ୍ତରାଷ୍ଟ୍ର ଆମେରିକାରେ ଏହାର ମୂଲ୍ୟ ପ୍ରତ୍ୟେକ ଡୋଜ ପିଛା ୦.୦୫ ଆମେରିକୀୟ ଡଲାର । ^[୨]

ଆଧାର[ସମ୍ପାଦନା]

↑ ^୧.୦ ^୧.୧ Gardner JD, Ciociola AA, Robinson M, McIsaac RL (July 2002). "Determination of the time of onset of action of ranitidine and famotidine on intra-gastric acidity". Aliment. Pharmacol. Ther. 16 (7): 1317–1326. doi:10.1046/j.1365-2036.2002.01291.x. PMID 12144582.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ "Ranitidine". The American Society of Health-System Pharmacists. Retrieved Dec 1, 2015.
↑ Fedorowicz, Z; van Zuuren, EJ; Hu, N (14 March 2012). "Histamine H2-receptor antagonists for urticaria". The Cochrane database of systematic reviews. 3: CD008596. doi:10.1002/14651858.CD008596.pub2. PMID 22419335.
↑ Tleyjeh, IM; Abdulhak, AB; Riaz, M; Garbati, MA; Al-Tannir, M; Alasmari, FA; Alghamdi, M; Khan, AR; Erwin, PJ; Sutton, AJ; Baddour, LM (2013). "The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis". PLOS ONE. 8 (3): e56498. doi:10.1371/journal.pone.0056498. PMC 3587620. PMID 23469173.
↑ Fischer, Janos (2010). Analogue-based Drug Discovery II. John Wiley & Sons. p. 4. ISBN 9783527632121.
↑ Hara, Takuji (2003). Innovation in the pharmaceutical industry the process of drug discovery and development. Cheltenham, U.K.: Edward Elgar. p. 94. ISBN 9781843765660.
↑ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
↑ "Ranitidine". International Drug Price Indicator Guide. Retrieved 1 December 2015.

[pmid12144582-1] ୧.୦ ^୧.୧ Gardner JD, Ciociola AA, Robinson M, McIsaac RL (July 2002). "Determination of the time of onset of action of ranitidine and famotidine on intra-gastric acidity". Aliment. Pharmacol. Ther. 16 (7): 1317–1326. doi:10.1046/j.1365-2036.2002.01291.x. PMID 12144582.

[AHFS2015-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ "Ranitidine". The American Society of Health-System Pharmacists. Retrieved Dec 1, 2015.

[3] Fedorowicz, Z; van Zuuren, EJ; Hu, N (14 March 2012). "Histamine H2-receptor antagonists for urticaria". The Cochrane database of systematic reviews. 3: CD008596. doi:10.1002/14651858.CD008596.pub2. PMID 22419335.

[4] Tleyjeh, IM; Abdulhak, AB; Riaz, M; Garbati, MA; Al-Tannir, M; Alasmari, FA; Alghamdi, M; Khan, AR; Erwin, PJ; Sutton, AJ; Baddour, LM (2013). "The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis". PLOS ONE. 8 (3): e56498. doi:10.1371/journal.pone.0056498. PMC 3587620. PMID 23469173.

[5] Fischer, Janos (2010). Analogue-based Drug Discovery II. John Wiley & Sons. p. 4. ISBN 9783527632121.

[6] Hara, Takuji (2003). Innovation in the pharmaceutical industry the process of drug discovery and development. Cheltenham, U.K.: Edward Elgar. p. 94. ISBN 9781843765660.

[7] "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.

[8] "Ranitidine". International Drug Price Indicator Guide. Retrieved 1 December 2015.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]